文献速递眼底病与葡萄膜炎

LIGHTSITE III:使用Lumithera Valeda光递送系统进行多波长光生物调节治疗非渗出性(干性)年龄相关性黄斑变性的13个月疗效与安全性评估

LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.
PubMed 文献 · Retina · 2024-01-01

LIGHTSITE III是一项随机对照试验,评估多波长光生物调节(PBM,590、660、850 nm)治疗干性年龄相关性黄斑变性(AMD)的13个月疗效与安全性。共随机100例受试者(148眼),每4个月接受3至5周内9次治疗。PBM组(91眼)与假治疗组(54眼)最佳矫正视力组间差异为2.4个字母(SE 1.15),CI:-4.7至-0.1,P=0.02;PBM组新发地图样萎缩显著减少(P=0.024,Fisher精确检验,比值比9.4),安全性良好。

要点

  • LIGHTSITE III达到主要疗效终点:PBM组与假治疗组最佳矫正视力组间差异2.4个字母(SE 1.15),CI:-4.7至-0.1,P=0.02。
  • PBM组新发地图样萎缩显著减少(P=0.024,Fisher精确检验,比值比9.4)。
  • 多波长PBM(590、660、850 nm)在干性AMD中观察到良好的安全性特征。

核心结论

  • LIGHTSITE III是一项前瞻性、随机、对照试验,显示中间型干性AMD接受PBM治疗后临床和解剖学结局改善。

研究设计与样本

  • LIGHTSITE III是随机对照试验,评估PBM治疗干性AMD的安全性和有效性。
  • 受试者接受多波长PBM(590、660、850 nm)或假治疗,每4个月在3至5周内进行9次治疗,持续24个月。
  • 共随机100例受试者(148眼)干性AMD,本报告呈现13个月分析数据。

主要发现

  • LIGHTSITE III达到主要疗效最佳矫正视力终点:PBM组(91眼)与假治疗组(54眼)组间差异2.4个字母(SE 1.15),CI:-4.7至-0.1,P=0.02。
  • PBM组单独分析:5.4个字母(SE 0.96),CI:3.5至7.3,P<0.0001;假治疗组单独分析:3.0个字母(SE 1.13),CI:0.7至5.2,P<0.0001。
  • PBM组新发地图样萎缩显著减少(P=0.024,Fisher精确检验,比值比9.4)。
  • 观察到良好的安全性特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The LIGHTSITE III study evaluated multiwavelength photobiomodulation (PBM) therapy in nonexudative (dry) age-related macular degeneration (AMD) using the LumiThera Valeda Light Delivery System. METHODS: LIGHTSITE III is a randomized, controlled trial to assess the safety and effectiveness of PBM in dry AMD. Subjects were given multiwavelength PBM (590, 660, and 850 nm) or Sham treatment delivered in a series of nine sessions over 3 to 5 weeks every four months over 24 months. Subjects were assessed for efficacy and safety outcomes. Data from the 13-month analysis are presented in this report. RESULTS: A total of 100 subjects (148 eyes) with dry AMD were randomized. LIGHTSITE III met the primary efficacy best-corrected visual acuity endpoint with a significant difference between PBM (n = 91 eyes) and Sham (n = 54 eyes) groups (Between group difference: 2.4 letters (SE 1.15), CI: -4.7 to -0.1, P = 0.02) (PBM alone: 5.4 letters (SE 0.96), CI: 3.5 to 7.3, P < 0.0001; Sham alone: 3.0 letters (SE 1.13), CI: 0.7-5.2, P < 0.0001). The PBM group showed a significant decrease in new onset geographic atrophy ( P = 0.024, Fisher exact test, odds ratio 9.4). A favorable safety profile was observed. CONCLUSION: LIGHTSITE III provides a prospective, randomized, controlled trial showing improved clinical and anatomical outcomes in intermediate dry AMD following PBM therapy.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Boyer D, Hu A, Warrow D, et al. LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System. Retina. 2024. PMID: 37972955. doi:10.1097/IAE.0000000000003980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。